We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Forge

News List

GentiBio, Forge Biologics Ink Development and Manufacturing Agreement contractpharma
July 19, 2021
GentiBio and Forge Biologics have entered a development and manufacturing partnership to advance GentiBio’s immune tolerance platform.
Forge Biologics Announces Multiple FDA Designations for Krabbe Disease Therapeutic americanpharmaceuticalreview
February 19, 2021
Forge Biologics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan Drug, and Rare Pediatric Disease (RPD) designations to FBX-101 for the treatment of patients with Krabbe disease.
Forge Receives Notice of Allowance from USPTO Covering Novel Chemistry Targeting LpxC americanpharmaceuticalreview
August 15, 2019
Forge Therapeutics announced the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application directed to compositions of matter and methods of use of certain 'non-hydroxamate' inhibitors of LpxC for the tr